

**Maryland Board of Pharmacy  
Public Board Meeting**

**Meeting Minutes  
April 18, 2018**

<b>Name</b>	<b>Title</b>	<b>Present</b>	<b>Absent</b>
Ashby, D.	Commissioner	X	
Bouyoukas, S.	Commissioner	X	
Evans, K.	Commissioner	X	
Gavgani, M.	Commissioner/President	X	
Hardesty, J.	Commissioner	X	
Leikach, N.	Commissioner	X	
Morgan, K.	Commissioner/Treasurer	X	
Oliver, B.	Commissioner	X	
Peters, R.	Commissioner	X	
St. Cyr, II, Z. W.	Commissioner/Secretary	X	
Toney, R.	Commissioner	X	
Yankellow, E.	Commissioner	X	
Bethman, L.	Board Counsel	X	
Felter, B.	Staff Attorney	X	
Speights-Napata, D.	Executive Director	X	
Fields, E.	Deputy Director of Operations	X	
Sanderoff, L.	Investigation/Supervisor	X	
Logan, B.	Legislation/Regulations Manager	X	
Brand, E.	Licensing Manager	X	
Evans, T.	Compliance Director	X	
Chew, C.	Management Associate	X	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
<b>I. Executive Committee Report(s)</b>	<p data-bbox="342 224 559 284"><b>A.) M. Gavgani, Board President</b></p> <p data-bbox="342 824 534 885"><b>B.) Z. St. Cyr, II, Secretary</b></p>	<p data-bbox="585 224 1178 349"><i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i></p> <ol data-bbox="634 423 1229 885" style="list-style-type: none"> <li data-bbox="634 423 981 448">1. <b>Call to Order 9:38AM.</b></li> <li data-bbox="634 493 1229 618">2. <b>Sign-in Introduction and of meeting attendees</b> – <i>(Please indicate on sign-in sheet if you are requesting CE Units for attendance)</i></li> <li data-bbox="634 662 1129 722">3. <b>Distribution of Agenda and packet materials</b></li> <li data-bbox="634 766 1229 885">4. <b>Review and approve February 2018 Public Meeting Minutes</b> <i>(Note: March 2018 meeting was canceled due to inclement weather)</i></li> </ol>	<p data-bbox="1257 423 1619 521">M. Gavgani recognized to the attendance of former Board President Don Taylor.</p> <p data-bbox="1257 760 1661 889">Motion by K. Morgan to approve the February 2018 Public Meeting minutes; 2<sup>nd</sup> by D. Ashby.</p>	<p data-bbox="1683 760 1949 820">4. The Board voted to approve this motion.</p>
<b>II. A. Executive Director Report</b>	<b>D. Speights-Napata, Executive Director</b>	<ol data-bbox="634 959 1129 1425" style="list-style-type: none"> <li data-bbox="634 959 938 984">1. <b>Operations Updates</b></li> <li data-bbox="634 1027 902 1052">2. <b>Meetings Update</b></li> <li data-bbox="634 1096 1129 1425"> <ol data-bbox="634 1096 1129 1425" style="list-style-type: none"> <li data-bbox="634 1096 1129 1120">a. <b>Contraceptive stakeholder meeting</b></li> <li data-bbox="634 1393 959 1417">b. <b>ASCP spring meeting</b></li> </ol> </li> </ol>	<p data-bbox="1257 1096 1651 1356">a. Contraceptive Regulation Stake Holder meeting will resume, the first meeting will be held Monday, May 14<sup>th</sup>. These meeting are to develop form and algorithms that are required for the implementation of the regulations.</p> <p data-bbox="1257 1393 1613 1453">b. Legislative update on the Contraceptive regulation was</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p><b>c. NABP annual meeting</b></p> <p><b>d. Pharmacy Technician member seat</b></p> <p><b>e. MSHP (Maryland Society of Health-System Pharmacy)</b></p>	<p>provided at the ASCP (American Society of Consultant Pharmacist) spring meeting. Commissioner J. Hardesty also presented during the meeting. Items of concern were mentioned, and shared with Board staff.</p> <p>c. NABP will host its annual meeting May 4<sup>th</sup>-9<sup>th</sup> in Denver, CO. The Board will present two posters for review during the annual meeting out of fifteen submitted statewide. The topics of choice are, Contraceptive Regulation and Naloxone and the implementation and standards in Maryland.</p> <p>d. D. Speights-Napata provided the Commissioners with information on ten State Boards that have pharmacy technician seats on their Boards, for review, and possible implementation. A brief discussion was held surrounding this topic.</p> <p>e. Commissioner D. Ashby attended the MSHP meeting on behalf of President Gavgani and Executive Director Speights-Napata, due to scheduling conflicts. Greetings were well received for the Board's presence. President Gavgani's</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p><b>f. Rite Aid change of ownership</b>  <b>Thomas Evans</b>  <b>Compliance Director</b>  <b>Maryland BOP</b></p> <p><b>g. NABP website and Intern Application</b>  <b>Etzion Brand</b>  <b>Licensing Manager</b>  <b>Maryland BOP</b></p>	<p>eight years of leadership was acknowledged during the meeting. The Pharmacy leadership group also held a meeting and by D. Ashby was in attendance. Topics of discussion were the PDMP mandates, and the Maryland Technician Consensus Conference, which is to be held June 21<sup>st</sup> at the Mt. Washington Conference Center. The planning committee is designing a survey for feedback within the State regarding Technician education.</p> <p>f. T. Evans reported 97 Rite Aid pharmacies changed ownership to Walgreens. Inspectors were required to inspect all stores, inspections were completed within 3wks. All work was performed during the transition from CitiDirect and Wells Fargo banks.</p> <p>g. E. Brand-NABP new website launch has taken place for a paperless process. There is data in NABP old database that can only be accessed once information is requested from applicants. Information is limited, and other avenues have to be explored to obtain information. Inquiries submitted directly to NABP will be</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
			<p>addressed to applicants by April 25<sup>th</sup>. Intern Application-A student has to finish their first as an Intern before they are able to register with the Board. Affidavits are being completed prior to their first year of completion. The Board is currently revising the instructions for State schools to have affidavits reflect completion of the first year, or have students apply as Technicians. The overview was followed by Q&amp;A from the Board and audience.</p>	
<p><b>B. Operations Report</b></p>	<p><b>E. Fields, Deputy Director/ Operations</b></p>	<p><b>1. Administration and Public Support (APS) Unit Updates</b></p> <p><b>a) Accounting Report through March 31, 2018</b></p> <p><b>b) Rehabilitative Services Contract Update</b></p>	<p>1a. A report on Board revenue and expenses for the month of March was provided. Revenue is high due to Pharmacy renewal season. The Maryland Healthcare commission receives twenty six dollars of every pharmacist renewal. Expected year end expense will equal \$136,000.00.</p> <p>1b. The Rehabilitative Services contract is currently being reviewed at the University of Maryland.</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results																														
		<p><b>2. Management Information Systems (MIS) Unit Updates</b></p> <p><b>a) Pharmacy Online Renewal Revisions with System Automation</b></p>	<p>2a. Online pharmacy renewals will be rewritten after May, to model the distributor renewal process to eliminate difficulties renewing online. MIS is considering using a cloud base environment to house data through System Automation. This will eliminate costly maintenance fees, and obsolete servers, the agreement also includes updated licensing software to rewrite five applications.</p>																															
<p><b>C. Licensing</b></p>	<p><b>E. Brand/ Licensing Manager</b></p>	<p><b>1. Unit Updates</b></p> <p><b>2. March Monthly Statistics</b></p> <table border="1" data-bbox="640 873 1244 1396"> <thead> <tr> <th>License Type</th> <th>New</th> <th>Renewed</th> <th>Reinstated</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>Distributor</td> <td>21</td> <td>8</td> <td>0</td> <td>1,219</td> </tr> <tr> <td>Pharmacy</td> <td>13</td> <td>0</td> <td>0</td> <td>2,096</td> </tr> <tr> <td>Pharmacist</td> <td>43</td> <td>382</td> <td>0</td> <td>11,704</td> </tr> <tr> <td>Vaccination</td> <td>13</td> <td>27</td> <td>0</td> <td>4,622</td> </tr> <tr> <td>Pharmacy Intern - Graduates</td> <td>3</td> <td>0</td> <td>0</td> <td>48</td> </tr> </tbody> </table>	License Type	New	Renewed	Reinstated	Total	Distributor	21	8	0	1,219	Pharmacy	13	0	0	2,096	Pharmacist	43	382	0	11,704	Vaccination	13	27	0	4,622	Pharmacy Intern - Graduates	3	0	0	48		
License Type	New	Renewed	Reinstated	Total																														
Distributor	21	8	0	1,219																														
Pharmacy	13	0	0	2,096																														
Pharmacist	43	382	0	11,704																														
Vaccination	13	27	0	4,622																														
Pharmacy Intern - Graduates	3	0	0	48																														

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	----------------------------------	---------

		<table border="1"> <tr> <td>Pharmacy Intern - Students</td> <td>17</td> <td>22</td> <td>0</td> <td>834</td> </tr> <tr> <td>Pharmacy Technician</td> <td>135</td> <td>297</td> <td>3</td> <td>9,790</td> </tr> <tr> <td><b>TOTAL</b></td> <td><b>245</b></td> <td><b>736</b></td> <td><b>3</b></td> <td><b>30,313</b></td> </tr> </table>	Pharmacy Intern - Students	17	22	0	834	Pharmacy Technician	135	297	3	9,790	<b>TOTAL</b>	<b>245</b>	<b>736</b>	<b>3</b>	<b>30,313</b>																																
Pharmacy Intern - Students	17	22	0	834																																													
Pharmacy Technician	135	297	3	9,790																																													
<b>TOTAL</b>	<b>245</b>	<b>736</b>	<b>3</b>	<b>30,313</b>																																													
		<p><b>1. April Monthly Statistics</b></p> <table border="1"> <thead> <tr> <th>License Type</th> <th>New</th> <th>Renewed</th> <th>Reinstated</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>Distributor</td> <td>20</td> <td>5</td> <td>0</td> <td>1,234</td> </tr> <tr> <td>Pharmacy</td> <td>105</td> <td>239</td> <td>0</td> <td>2,159</td> </tr> <tr> <td>Pharmacist</td> <td>25</td> <td>432</td> <td>0</td> <td>11,692</td> </tr> <tr> <td>Vaccination</td> <td>18</td> <td>9</td> <td>0</td> <td>4,641</td> </tr> <tr> <td>Pharmacy Intern - Graduates</td> <td>2</td> <td>0</td> <td>0</td> <td>49</td> </tr> <tr> <td>Pharmacy Intern - Students</td> <td>18</td> <td>11</td> <td>0</td> <td>833</td> </tr> <tr> <td>Pharmacy Technician</td> <td>102</td> <td>375</td> <td>3</td> <td>9,777</td> </tr> <tr> <td><b>TOTAL</b></td> <td><b>297</b></td> <td><b>1,071</b></td> <td><b>3</b></td> <td><b>30,407</b></td> </tr> </tbody> </table>	License Type	New	Renewed	Reinstated	Total	Distributor	20	5	0	1,234	Pharmacy	105	239	0	2,159	Pharmacist	25	432	0	11,692	Vaccination	18	9	0	4,641	Pharmacy Intern - Graduates	2	0	0	49	Pharmacy Intern - Students	18	11	0	833	Pharmacy Technician	102	375	3	9,777	<b>TOTAL</b>	<b>297</b>	<b>1,071</b>	<b>3</b>	<b>30,407</b>		
License Type	New	Renewed	Reinstated	Total																																													
Distributor	20	5	0	1,234																																													
Pharmacy	105	239	0	2,159																																													
Pharmacist	25	432	0	11,692																																													
Vaccination	18	9	0	4,641																																													
Pharmacy Intern - Graduates	2	0	0	49																																													
Pharmacy Intern - Students	18	11	0	833																																													
Pharmacy Technician	102	375	3	9,777																																													
<b>TOTAL</b>	<b>297</b>	<b>1,071</b>	<b>3</b>	<b>30,407</b>																																													

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
D. Compliance	T. Evans Pharmacist Inspector	<p><b>1. Unit Updates</b></p> <p><b>2. Monthly Statistics</b></p> <p><b>Complaints &amp; Investigations:</b></p> <p>New Complaints – 48  Resolved (Including Carryover) –0  Actions within Goal – 0/0  Final disciplinary actions taken – 0  Summary Actions Taken – 0  Average days to complete - 0</p> <p><b>Inspections:</b></p> <p>Total – 202  Annual Inspections - 95  Opening Inspections - 4  Closing Inspections – 1  Relocation/Change of Ownership Inspections – 101  Board Special Investigation Inspections – 1</p>		
E. Legislation & Regulations	B. Logan, Legislation and Regulations Manager	<p><u><b>1. COMAR 10.34.05.05 Security Responsibilities</b></u></p> <p><u><b>2. COMAR 10.34.32.03 D Requirements to Administer Vaccinations</b></u></p> <p><u><b>3. COMAR 10.34.40 Pharmacist Prescribing and Dispensing Contraceptives</b></u></p>	<p>1. This regulation was presented to the prior to the moratorium; revisions to the bill to reflect the health and safety of Marylanders.</p> <p>2. This regulation will require an updated sign in sheet, and revision to reflect the health and safety of Marylanders.</p> <p>3. Following discussion, a motion by the Practice</p>	



Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p><u>3.a. Comment from NACDS/MACDS</u>  <u>3.b. Response to NACDS/MACDS</u></p> <p><u>3.c. Comment from MPhA</u>  <u>3.d. Response to MPhA</u></p> <p><u>3.e. Comment MedChi/MDAAP/MDAEOG</u></p> <p><u>3.f. Comment Kaiser Permanente</u>  <u>3.g. Response to Kaiser Permanente</u></p> <p><u>3.h. Comment MSHP</u>  <u>3.i. Response MSHP</u></p> <p><u>4. COMAR 10.34.30 Applications</u></p> <p><u>5 HB 591 and SB549 Health Occupations - Physician Assistants - Dispensing of Drugs Under a Delegation Agreement</u> This bill authorizes a physician assistant to personally prepare and dispense a drug that the physician assistant is authorized to prescribe under a delegation agreement if the supervising physician possesses a dispensing permit.  <b>Support with Amendments</b></p> <p><u>6. HB0601 and SB1255 Public Health - Opioids - Dispensing Requirement</u> The proposed legislation requires that an opioid be dispensed with a nontoxic</p>	<p>Committee to ratify response; 2<sup>nd</sup> by E. Yankellow.</p> <p>4. The proposed regulation to address applications that have been pending over one year. The Practice Committee recommends approval of amended language “expiring after one year. Motion by E. Yankellow to approve language; 2<sup>nd</sup> by S. Bouyoukas.</p> <p>5. October 1, 2018 effective date</p> <p>6. HB0601 and SB1255 –No position</p>	<p>3. The Board voted to approve this motion.</p> <p>4. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>composition designed to deactivate and dispose of the opioid. <b>No Position</b></p> <p><b><u>7. HB653 and SB522 Health Care Providers - Opioid Prescriptions - Discussion of Information and Risks</u></b> This proposal would require certain “health care providers” to discuss the risk of certain opioids with certain patients. The bill relates to prescribing and not dispensing. <b>No Position</b></p> <p><b><u>8. HB922 Maryland Department of Health - "Pill Mill" Tip Line</u></b> This bill requires the Maryland Department of Health (MDH) to identify by December 1, 2018, a method for establishing a tip line for a person to report a licensed prescriber whom the person suspects is prescribing or overprescribing medication. <b>No Position</b></p> <p><b><u>9. HB1035 and SB1063 Natalie M. LaPrade Medical Cannabis Commission - Certifying Providers - Referrals</u></b> This bill, under the State’s medical cannabis program, prohibits a referral of a qualifying patient to a certifying provider by any person or entity who has any specified employment or compensation interest in facilitating a person. <b>No Position</b></p> <p><b><u>10. HB1063 Physicians - Dispensing Permit Exemption - Prepackaged Topical</u></b> This bill authorizes physicians to personally dispense a “prepackaged topical” without a dispensing permit.</p> <p><b><u>11. HB1452 and SB1223 Controlled Dangerous Substances Registration - Authorized Providers - Continuing Medical Education</u></b> This bill requires an authorized provider of controlled dangerous substances (CDS) to attest to the Maryland</p>	<p>7. October 1, 2018 effective date.</p> <p>8. July 1, 2018 effective date.</p> <p>9. HB1035 and SB1063-No Position</p> <p>10. HB1063 was withdrawn.</p> <p>11. October 1, 2018 effective date.</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Department of Health (MDH) that the authorized provider has completed two hours of specified continuing education. <b>No Position</b></p> <p><b><u>12. HB1558: Pharmacists - Dispensing of Prescription Drugs - Single Dispensing of Dosage Units</u></b> This bill authorizes a pharmacist to dispense, in a single dispensing and in exercising the professional judgment of the pharmacist, a quantity of a prescription drug that (1) is up to the total number of dosage units authorized by the original prescription and any refills; and (2) does not exceed a 90-day supply of the drug. <b>Letter of Concern</b></p> <p><b><u>13. HB1752: Aids for the Cessation of Tobacco Product Use - Prescribing and Dispensing by Pharmacists and Health Insurance Coverage</u></b> This bill authorizes a pharmacist who meets the requirements of certain regulations to prescribe and dispense medications approved by the U.S. Food and Drug Administration as an aid for cessation of the use of tobacco products; requires the State Board of Pharmacy to adopt certain regulations by September 1, 2019. <b>Letter of Support.</b></p> <p><b><u>14. Prescription Drug Monitoring Program - Prescription Monitoring Data - Insurance Carriers</u></b> This bill requires the Prescription Drug Monitoring Program (PDMP) to disclose prescription monitoring data to a health insurance carrier for the purpose of determining medical necessity of a prescription drug claim. <b>Letter of Concern</b></p>	<p>12. October 1, 2018 effective date.</p> <p>13. HB1752-Letter of support.</p> <p>14. Letter of concern.</p> <p>Information only-HB 88 was approved. Office of Controlled Substance will now decide if</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
			they need to send cases to Md Board of Pharmacy for action Information only-HB631 approved. Not on April agenda. Price Gauging for WS Distributors. AG will now have the authority to review price changes when there is a significant price change.	
<b>III. Committee Reports</b>  <b>A. Practice Committee</b>	<b>R. Peters, Chair</b>	<p><b><u>Lisa Burdick, R.K. Associates</u></b></p> <p>COP markets Colgate oral care products to the dental profession. Part of the product line is a prescription fluoride named Preident 5000. There are several variants of Preident 5000, all requiring a prescription from a licensed dentist. We are reaching out to all of the United States to determine whether Colgate's pre-printed prescription pads are in compliance with state regulations. I have attached a copy of Colgate's generic pad for your review and comment as it has been Colgate's understanding that Maryland is one of the states that accepts a multi-state generic pad. As you can see, it is pre-printed with the product information but the licensed dentist does need to complete the pad with his and the patient's name, address, etc., as well as instructions for product use. I'm sorry the back of the pad did not reproduce very well. It has language regarding the number and type of tamper resistant features that the prescription paper contains.</p> <p><b><u>Response:</u></b> Please be advised, pursuant to Annotated Code of Maryland, Health Occupations, §12-313 (b) (11), a pharmacist is prohibited from providing a prescriber with forms that bear the name or other</p>	<p>1.a. Motion by Committee to approve draft response; 2<sup>nd</sup> by D. Ashby.</p>	<p>a. Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>means of identification of a pharmacy or pharmacist. The Maryland Pharmacy Act does not address the issue you have presented, namely, a company providing pre-printed prescription pads. You should contact the Maryland Dental Board for guidance on this matter.</p> <p><b><u>Farangis Rafi</u></b></p> <p>A very prominent and extremely large outpatient surgical center group with multiple locations wants the pharmacy to provide them with blister packs that contain a combination of prescription medications.</p> <ol style="list-style-type: none"> <li>1. Can a retail independent pharmacy fulfill this request? N/A</li> <li>2. Does this require a purchase order from the center or do they simply have to send a "for office use" prescription to the pharmacy. N/A</li> <li>3. Is there a quantity limitation of what the pharmacy can supply? N/A</li> <li>4. Can these blister packs be mailed out to the centers or do they have to be picked up/hand delivered? N/A</li> <li>5. If the surgical centers are in surrounding states can we still fulfill their orders? N/A</li> <li>6. What limitations if any would we encounter if this blister-pack becomes a formulary standard for all of their procedures? N/A</li> <li>7. If hospital centers were to order as well, would the same laws apply? N/A</li> </ol> <p><b><u>Response:</u></b> Please be advised that you will have to be registered with the FDA as a repackager. "Repackagers" are required to be licensed in Maryland as Wholesale Distributors. (See Health</p>	<p>1.b. Motion by Committee to approve draft response; 2<sup>nd</sup> by S. Bouyoukas.</p> <p>1.c. Motion by Committee to approve draft response; 2<sup>nd</sup> by D. Ashby.</p>	<p>b. Board voted to approve this motion.</p> <p>c. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Occupations Article, 12-6C-01(r), Annotated Code of Maryland.)</p> <p><b><u>Ms. N. Lois Adams, B. Pharm., MBA, CRPh</u></b>  <b><u>President &amp; CEO</u></b>  <b><u>HHCS Health Group of Companies, LLC</u></b>  <b><u>Freedom Pharmacy &amp; Cystic Fibrosis Pharmacy</u></b></p> <p>To whom it may concern, we are writing in request for an advisory opinion as to whether or not in your state two commonly owned and managed pharmacies located at the same physical address can lawfully provide central fill or pharmacy coverage for one another. If the answer is yes, is it required to have a central fill agreement? Is it required to seek BOP approval? Please outline the steps needed to provide central fill coverage.</p> <p>Would this central fill relationship require more than one permit? If the relationship does not require a "central fill" agreement because the pharmacies are commonly owned and located in the same place, will a single out of state permit suffice?</p> <p><b><u>Response:</u></b> Please be advised that the two commonly owned pharmacies will each need a pharmacy permit pursuant to <i>Annotated Code of Maryland Health Occupations. §12-401 (b)</i>. With regard to central fill agreement, the Maryland Pharmacy Act does not address such an agreement. Please reference, <i>Code of Maryland Regulations (COMAR) 10.34.04, Chapter 04 Transfer and Outsourcing of Prescriptions and Prescription Orders</i>.</p> <p>All of these Resolutions will be discussed and voted on at NABP convention in Colorado. They have already been</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>voted on by each district. Once voted on in Colorado then full details will be provided</p> <p>Resolutions for District 1-Implementation of and regulation of technology in pharmacy practice, wants NABP to encourage communicate that outdated statues need to be updated and replace with NABP model language  Safety resolution for compounding and dispensing of compounding products. Wants NABP to work with USP and other stakeholders to provide information USP Chapter 800 concerning hazardous materials  Electronic Transmission of prescriptions by district 1 co-supported by District 4. Create a task force examine feasibility that member boards ensure all prescriptions be transmitted electronically.</p> <p>Collaborate with Veterinary pharmacy education and dispensing medications for veterinarians.</p> <p>Resolutions for District 4  Establish a Task Force on changes on model act. Establish information and improving interactions for technician standards.</p> <p>Resolutions for District 7  Establish a taskforce to develop Standard of Care, co-supported by district 4, 6 and 8 – from prescriptive rule based highlight the tools that Boards of Pharmacy may need to make this transition</p> <p>Resolutions for District 8  Cooperative interstate investigation Act- NABP and their staff will contact request a letter of assurance. When a licensee of one state has a dispensing error from state that pharmacist is not licensed will accept the complaint from offending state</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Cannabis medications-prescription medication to treat epilepsy and other syndromes has been shown to have allergies, and inflammatory affects. Products should be subject to state law and they want NABP to collaborate with interested stakeholders to encourage and assist on this</p> <p>Compounding for research purposes-NABP pharmacy act language model from FDA and NIH not be considered for compounding</p>		
<p><b>B. Licensing Committee</b></p>	<p><b>D. Ashby, Chair</b></p>	<p><b>1. Review of Pharmacist Applications:</b></p> <p>a) <del>#114953</del>- The applicant is requesting a refund of \$150 from his reciprocity fee. The applicant is currently licensed in VA. In November 2017, he submitted a reciprocity application with the application fee of \$300. He did not realize that he could have filed a new application for \$150. He is requesting that he be refunded \$150 and that \$150 be applied to the new initial examination application that he has submitted. <i>Licensing Committee's Recommendation:</i> Approve.</p> <p>b) <del>#115667</del>- The applicant is requesting a waiver of the requirement to have worked in a pharmacy for 520 hours in order to obtain a license via reciprocity. He was licensed in Washington, DC, in January 2018. <i>Licensing Committee's Recommendation:</i> Deny. Application by examination is available.</p>	<p>1a) Motion by Committee to approve refund; 2<sup>nd</sup> by R. Toney.</p> <p>1b) Motion by Committee to deny waiver; 2<sup>nd</sup> by B. Oliver.</p>	<p>a) The Board voted to approve this motion.</p> <p>b) The Board voted to approve the motion.</p>



Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>c) <del>#111528</del>- The applicant is licensed in the state of Oklahoma. Her reciprocity application expired on February 22, 2018. Her MPJE was scheduled for February 20, 2018, but it was canceled due to inclement weather in Oklahoma. She checked immediately for available opportunities to reschedule at all three of the testing sites in the state, but there were no testing appointments available within the short timeframe. She took the MPJE on March 3, 2018, and passed. The applicant requested an extension of her reciprocity application expiration date for a short period until she was able to take the MPJE exam.  <u>Licensing Committee's Recommendation:</u>  Approve a 60-day extension.</p> <p>2. <b>Review of Pharmacy Intern Applications:</b>  NONE</p> <p>3. <b>Review of Pharmacy Technician Applications:</b> NONE</p> <p>4. <b>Review of Distributor Applications:</b>  NONE</p> <p>5. <b>Review of Pharmacy Applications:</b> NONE</p> <p>6. <b>Review of Pharmacy Technicians Training Programs:</b></p> <p>a) <b>Weis Markets</b>  <u>Licensing Committee's Recommendation:</u>  Approve</p>	<p>1c) Motion by Committee to approve 60-day extension; 2<sup>nd</sup> by E. Yankellow.</p> <p>6a) Motion by Committee to approve; 2<sup>nd</sup> by S. Bouyoukas.</p>	<p>c) The Board voted to approve the motion.</p> <p>d) The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>b) <b>Anne Arundel Community College</b> <u>Licensing Committee's Recommendation:</u> Approve</p> <p>7. <b>New Business:</b></p> <p>a) <b>CE approval request-</b> Pharmacist requests CE credit for a CPR course. <u>Licensing Committee's Recommendation:</u> Deny. Not sufficiently related to the practice of pharmacy.</p> <p>b) <b>#111680-</b> The applicant is requesting an extension of his application expiration date March 6, 2018. Immediately after filing the application, the applicant went to Ethiopia to care for his father for two months (March 2017 – May 2017). He returned there in September 2017 – October 2017, and in January 2018. He took the MPJE in February and scored 74. He will be leaving again to care for his father in Ethiopia from April 15, 2018, until June 16, 2018. <u>Licensing Committee's Recommendation:</u> Approve six-month extension (from March 6, 2018, expiration date).</p>	<p>6b) Motion by Committee to approve; 2<sup>nd</sup> by B. Oliver.</p> <p>7a) Motion by Committee to deny; 2<sup>nd</sup> by S. Bouyoukas.</p> <p>7b) Motion by Committee to approve six month extension; 2<sup>nd</sup> by B. Oliver.</p>	<p>e) The Board voted to approve this motion.</p> <p>f) The Board voted to approve this motion.</p> <p>g) The Board voted to approve this motion.</p>
<b>C. Public Relations Committee</b>	<b>E. Yankellow, Chair</b>	<p><b>Public Relations Committee Update:</b></p> <ul style="list-style-type: none"> <li>• <b>The Committee met March 28<sup>th</sup> and there were several topics of discussion.</b></li> <li>• <b>The published newsletter; the schedule for article submissions. The choice of articles to feature in upcoming newsletters. Live CPR training and vaccination being</b></li> </ul>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>hopeful articles, based on previous discussions.</p> <ul style="list-style-type: none"> <li>• Preparation for the October 2018 CE Breakfast. Three proposals have been received for possible venue locations, J. Seeds and N. Joran have been visiting those venues.</li> <li>• Topics and presenters are currently being discussed.</li> <li>• Public Outreach attendance at different meetings. In attendance at the ASCP meeting were J. Seeds staffing the exhibitors table, Commissioner R. Toney, E. Yankellow, and presenting were Commissioner J. Hardesty on long-term care regulation and the Executive Director on the contraceptive regulation.</li> </ul>		
D. Disciplinary	K. Morgan, Chair	<p>Disciplinary Committee Update:</p> <ul style="list-style-type: none"> <li>• The Committee met on April 4, 2018, and includes Commissioners R. Peters, B. Oliver, S. Bouyoukas, J. Hardesty.</li> <li>• A confidential discussion will be held in the Board's Closed Public Session.</li> </ul>		
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Update:		
IV. Other Business & FYI	M. Gavgani, President	<ul style="list-style-type: none"> <li>• Commissioner K. Morgan is in favor of technician seats on the Board. Commissioner D. Ashby recalled those in attendance during the National Consensus Conference also embracing the idea. Former President D. Taylor, commented that twenty five percent of technicians volunteer with Emergency Preparedness.</li> </ul>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	-------------------------------	---------

		<p><b>J. Phillip of Walgreens and Chair of the Florida Board, considers this being beneficial to offer a different perspective outside of Pharmacist input.</b></p> <ul style="list-style-type: none"> <li>• <b>Commissioner St. Cyr II asked if there were any organized associations in Maryland and nationwide that does test. A. Horton, MPhA, conveyed having Pharmacy Technicians members and work closely with PTCB. B. Levin representing Medstar and MSHP.</b></li> <li>• <b>President Gavgani spoke briefly to the attendees, Board Commissioners, Counsel, and Staff; to show gratitude for everyone's hard work and dedication in assisting her during both terms. She conveyed how the public has aided in the Boards growth. She thanked D. Taylor again for his presence and guidance.</b></li> <li>• <b>Commissioner St. Cyr II, thanked President Gavgani for her hard work and impact on the Board during her tenure as President.</b></li> <li>• <b>Commissioner R. Toney asked a question regarding the method of how meetings appear on the agenda that Commissioners attend. M. Gavgani and Commissioner St. Cyr II clarified, as long as they pertain to the Board they can be shared as other business, if not listed on the agenda.</b></li> </ul>		
--	--	---	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
V. Adjournment	M. Gavgani, President	<p>A. The Public Meeting was adjourned at 11:47A.M.</p> <p>B. M. Gavgani convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications.</p> <p>C. The Closed Public Session was adjourned. Immediately thereafter, M. Gavgani, convened an Administrative Session for purposes of discussing confidential disciplinary cases.</p> <p>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session.</p>	Motion to close the Public Board Meeting by D. Ashby; 2 <sup>nd</sup> by S. Bouyoukas.	The Board voted to approve this motion.

**PRESIDING OFFICER'S WRITTEN STATEMENT FOR CLOSING A MEETING ("CLOSING STATEMENT")  
UNDER THE OPEN MEETINGS ACT (General Provisions Article § 3-305)**

This form has two sides. Complete items 1 – 4:

1. Recorded vote to close the meeting: Date: 4/18/18; Time: 11:47 am; Location: 4201 Patterson Ave  
Motion to close meeting made by: D. Ashby Seconded by S. Bouyake  
Members in favor: unanimous; Opposed: none  
Abstaining: —; Absent: —

2. Statutory authority to close session (check all provisions that apply):

This meeting will be closed under General Provisions Art. § 3-305(b) only:

(1)\_\_\_ "To discuss the appointment, employment, assignment, promotion, discipline, demotion, compensation, removal, resignation, or performance evaluation of appointees, employees, or officials over whom this public body has jurisdiction; any other personnel matter that affects one or more specific individuals"; (2)\_\_\_ "To protect the privacy or reputation of individuals concerning a matter not related to public business"; (3)\_\_\_ "To consider the acquisition of real property for a public purpose and matters directly related thereto"; (4)\_\_\_ "To consider a matter that concerns the proposal for a business or industrial organization to locate, expand, or remain in the State"; (5)\_\_\_ "To consider the investment of public funds"; (6)\_\_\_ "To consider the marketing of public securities"; (7)  "To consult with counsel to obtain legal advice"; (8)\_\_\_ "To consult with staff, consultants, or other individuals about pending or potential litigation"; (9)\_\_\_ "To conduct collective bargaining negotiations or consider matters that relate to the negotiations"; (10)  "To discuss public security, if the public body determines that public discussion would constitute a risk to the public or to public security, including: (i) the deployment of fire and police services and staff; and (ii) the development and implementation of emergency plans"; (11)\_\_\_ "To prepare, administer, or grade a scholastic, licensing, or qualifying examination"; (12)\_\_\_ "To conduct or discuss an investigative proceeding on actual or possible criminal conduct"; (13)  "To comply with a specific constitutional, statutory, or judicially imposed requirement that prevents public disclosures about a particular proceeding or matter"; (14)\_\_\_ "Before a contract is awarded or bids are opened, to discuss a matter directly related to a negotiating strategy or the contents of a bid or proposal, if public discussion or disclosure would adversely impact the ability of the public body to participate in the competitive bidding or proposal process."

Continued →

3. For each provision checked above, disclosure of the topic to be discussed and the public body's reason for discussing that topic in closed session.

Citation (insert # from above)	Topic	Reason for closed-session discussion of topic
§3-305(b) ( ) 10	Emergency Preparedness and Response	Presentation on protocols and procedures for emergency response re: mass medication dispensing involves confidential security information
§3-305(b) ( )		regarding drug storage sites and subsequent distribution in the event of emergencies.
§3-305(b) ( ) 13	Confidential matters in license applications	Engaging in medical review committee deliberations regarding confidential matters contained in license applications
§3-305(b) ( ) 7	Obtain legal advice	Obtain legal advice re: options for processing applications
§3-305(b) ( )		

4. This statement is made by Mark [Signature], Presiding Officer.

\*\*\*\*\*

**WORKSHEET FOR OPTIONAL USE IN CLOSED SESSION: INFORMATION THAT MUST BE DISCLOSED IN THE MINUTES OF THE NEXT OPEN MEETING** Time of closed session:

11:47 AM Place: 4201 Patterson Ave Baltimore, Md.

Purpose(s): see above

Members who voted to meet in closed session: all members present in open session unless recused.

Persons attending closed session: all members present in open session + Don Taylor, ~~Andrew~~

Authority under § 3-305 for the closed session: § 3-305(b)(10) and (13)

Topics actually discussed: see above

Actions taken: (1) none (2) process applications <sup>accordingly</sup> Each recorded vote: unanimous

For a meeting recessed to perform an administrative function (§ 3-104): Time: 1:50 pm.

Place: 4201 Patterson Ave Persons present: same except J. Hardesty + D. Ashby Subject matter

discussed: complaints/investigations against licensees; bd. organizational chart and protocols for inspectors and legislative committee staff